Brief: Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the USA
29/04/2025 13:17
April 29 (Reuters) - Cullinan Therapeutics Inc CGEM.O: CULLINAN THERAPEUTICS TO INITIATE STUDY OF CLN-978, A BISPECIFIC CD19 T CELL ENGAGER ADMINISTERED SUBCUTANEOUSLY, IN PATIENTS WITH SJÖGREN’S DISEASE IN THE UNITED STATES Source text: ID:nGNX2yM1Wd Further company coverage: CGEM.O ((Reuters.Briefs@thomsonreuters.com;))